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LysosomesThe interactions of synthetically produced colloidal gold nanoparticles (GNPs) with living organisms are gaining
much attention in the biomedical sciences. While non-viral carriers, such as GNPs, are safer and more cost-
efﬁcient as compared to viral vectors, the probability of cell internalization is lower. In this paper, we discussed
a method to increase cell internalization of GNPs using a speciﬁc peptide known as “RME-Peptide”. Our results
showed an enhancement in cell uptake of peptide-capped GNPs. Furthermore, we investigated the exocytosis
process of peptide-capped GNPs. Our results showed that the peptide-modiﬁed GNPs had a lower number of
NPs exocytosed as compared to citrate-capped or as-made colloidal GNPs. Our study shows that bio-nano inter-
face can be improved using specially designed peptides on colloidal GNPs. The outcome of this research will be
beneﬁcial for their applications in therapeutics and imaging.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Nanotechnology-based approaches facilitate further development of
safer yetmore effective diagnostic and therapeuticmodalities for cancer
therapy [1,2]. The primary goal of nanoparticle (NP)-based platforms
will be the optimized delivery of therapeutics to tumors while causing
minimal damage to normal tissue and side effects to the patients
[3–7]. Among other NPs, Gold NPs (GNPs) are being used in cancer
research due to their biocompatibility and ability to act as both a
radiosensitizer and drug carrier in cancer therapy [8–12]. The design
of smart multifunctional NPs in order to improve current therapeutic
applications requires a thorough understanding of the mechanisms
behind nanoparticles (NPs) entering and leaving the cells. For drug
delivery, radiation therapy, and imaging applications, it is necessary to
control andmanipulate the accumulation of NPs for an extended period
of time within the cell. Previous studies have shown that both uptake
and removal mechanisms are dependent on the size, shape, and surface
properties of NPs. Among NP sizes between 13 and 100 nm, NPs of
diameter 50 nm showed the highest cell uptake [13]. Elucidating the
mechanism of uptake and removal of NPs in cells could lead to a better
understanding of NP toxicity. For example, if the NPs are trapped in
vesicles and leave the cells intact, they are unlikely to induce cellular
toxicity. Theoretical calculations support the size dependent NP uptake
[14]. Chithrani et al. have put forward a theoretical calculation toerson University, 350 Victoria
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. This is an open access article undersupport the NP removal process [15]. In most of these studies, NPs
took the endo-lyso path where NPs enter the cell through receptor-
mediated endocytosis (RME), are trapped in endosomes, fuse with
lysosomes for processing, and leave the cell via the exocytosis process.
During the endo-lyso path, NPs were localized in either endosomes or
lysosomes. The cell cytoplasm and nucleus were free of NPs. Nanoparti-
cles localized in the lysosomes exit the cell through exocytosis process.
Previous studies have shown that the path of NPs conjugated with
certain peptides is different from a regular endo-lyso path [16,17].
Nanoparticles conjugated with peptides containing integrin binding
domain can enter the cell via the endocytosis process followed by
escaping into the cytoplasm from endosomes [17,18]. These peptides
are also referred to as RME peptides since it enhances the RME process
[17,18]. Brust and co-workers suggested the approach of evading the
well-established endo-lyso pathway of uptake to a signiﬁcant extent,
either via the delivery of NPs by liposomes or by surface modiﬁcation
of the NPs with the supposed cell penetrating peptides (CPPs) [19].
The exocytosis process of NPs modiﬁed with peptides is not yet
known entirely. In this study, we used two peptides: 1) Pentapeptide
(sequence: H-Cys-Ala-Leu-Asn-Asn-OH) was used for stabilizing
NPs for peptide conjugation [20], and 2) RME peptide (sequence:
CKKKKKKGGRGDMFG) was used for endosomal escape and also to
improve NP uptake [17]. Our transmission electron microscopy (TEM)
images show that the RME peptide allows NPs to be released into the
cytoplasm (see Fig. 1). The endosomal escape of NPs reduced the rate
of the exocytosis process (as discussed later in this article). This increase
in residence time of GNPs within the cell may lead to improved
therapeutic applications.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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diameter. The citrate reduction method was used to synthesize GNPs.
Stock solutions of 1%HAuCl4were prepared and stored at room temper-
ature. Stock solutions of 1% sodium citrate were prepared fresh each
time. In the ﬁrst step, 300 μL of 1% chloroauric acid solution was
added to 30mL of deionizedwater in a round bottom ﬂask. Themixture
was brought to boiling on a hot platewhile being stirredwith amagnet-
ic stir bar. In the second step, 600 μL of 1% citrate solution was added to
the solution mixture and left on the hot plate for 5 min to complete the
reaction. The color of the solution changed from clear to dark blue to
red. The mixture was brought to room temperature while stirring.
Peptide-gold particle complexes were assembled by ﬁrst conjugating
the GNPs with the pentapeptide with approximately 300 peptides/
GNP ratio for stabilization purposes. Then the RME peptide was added
with 8 to 10 peptide/GNP ratio. Each peptide was prepared with a
terminal cystine group since cystine-terminated peptides can directly
bind to the GNP surface via a covalent sulfur\gold bond [16,21].
NP complexes were characterized using UV visible spectroscopy,
Dynamic Light Scattering (DLS), and zeta potential measurements
(see Supplementary Section S1). There was no signiﬁcant increase in
terms of the size of NPs following conjugation with the peptide accord-
ing to the DLS measurements. This is because the peptides were only
few nanometers in size. However, the zeta potential changes from a
negative value to a positive value. The negative charge of the non-
conjugated (citrate-capped) GNPs is due to citrate molecules on the
surface. Peptides are positively charged, and GNPs were positively
charged following conjugation with the peptides. The peptide-GNP
complexes were tested for their stability in cell culture media before
using them for cell uptake and transport studies.
The cellular uptake of peptide-GNP complexes was characterized by
using HeLa cells, a well-known human ﬁbroblast epithelial cell line. For
tissue culture studies, cells were grown in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at
37 °C in a humidiﬁed incubator with 5% CO2. The cells were incubated
with GNPs when the tissue culture dishes were 70–80% conﬂuent. We
have investigated the variation of NP distribution in cells internalized
with citrate-capped and peptide-capped NPs using TEM imaging. TheFig. 1.Nanoparticle transport pathway for peptide-capped NPs. A. Schematic showing the
endosomal escape of peptide-capped NPs into the cytoplasm. B. TEM images showing
localization of citrate-capped NPs in endosomes. C. Peptide-capped NPs escaped from
endosomes were localized in the cytoplasm. The scale bar is 100 nm.citrate-capped GNPs travel through the regular endo-lyso path causing
NPs to become trapped in either endosomes or lysosomes [13] while
most of the peptide-capped GNPs escaped from the endosomes and
got localized in the cytoplasm (see Fig. 1). For quantiﬁcation of the
GNP uptake, the cells were washed three times with PBS and
trypsinized. Cells were counted and then treated with HNO3 at 200 °C
in an oil bath for an Inductively Coupled Plasma-Atomic Emission Spec-
troscopy (ICP-AES) analysis. Details of the quantiﬁcation process are
given in Supplementary Section S2. The cellular uptake data proved
that the cells targeted with a RME peptide had the highest NP uptake,
as compared to cells targeted with citrate-capped NPs (Fig. 2). It is
believed that the synthetic RME peptide with an integrin binding
domain (RGD) supplemented an additional driving force for the cell
entry of NPs. In addition, positively charged NPs have a higher uptake
compared to negatively charged (citrated-capped)NPs [22]. Zeta poten-
tial measurements showed that peptide-capped GNPs were positively
charged (Supplementary Section S1). Hence, RME peptide and the
positive charge of the NPs may have caused the increased uptake of
peptide-modiﬁed NPs as compared to citrate-capped NPs.
Previous work has shown that the exocytosis process depends on
the cell type, NP size, and surface properties of NPs [15,23]. The exocy-
tosis of GNPs functionalizedwith nuclear targeting peptides is not prop-
erly known yet. Our studies have shown for the ﬁrst time that the
fraction of NPs exocytosed was lower by two-fold for cells targeted
with peptide-conjugatedNPs (Fig. 3). Citrate-cappedNPswere localized
in endosomes followed by processing via fusion with lysosomes. NPs
localized in lysosomes were excreted into the extracellular matrix
through fusing with the cell membrane. However, most of the GNPs
capped with peptides were able to enter the cytoplasm. This increase
in the residence time in the cytoplasm could lead to a slower exocytosis
process. Our results are in agreement with previously published work
for CuO NPs and silica NPs. For example, Wang et al. evaluated the
excretion of CuO NPs in A549 cells and discovered that a portion of
NPs, which were located in mitochondria and nucleus, could not be
excreted by the cells [24]. Similarly, based on ﬁndings by Chu et al.,
clusters of silica NPs in lysosomes are more easily exocytosed
by H1299 cells as compared to single NPs in the cytoplasm [25]. We
evaluated the exocytosis process as a function of time. To quantify NP
removal, cells pre-incubated with NPs for eight hours were washed
with PBS three times, introduced to fresh media supplemented with
FBS, and left in the incubator for monitoring the exocytosis process.
After one and six hour time points, the cell were rinsed three times
with PBS and trypsinized for quantiﬁcation of GNPs present per cell.
As illustrated in Fig. 3A, a signiﬁcant portion of the NPs were able to
re-enter the cells. The percentage of NPs re-entering the cells was 10%
and 15% respectively, for citrate-capped (non-targeted) and peptide-
capped NPs. Nuclear targeted NPs appeared to aggregate less within
the cell. Hence, it is possible for these NPs to re-enter cells once excret-
ed. This could be one of the reasons for an increase in NPs present in
cells targeted with peptides following a prolonged exocytosis process.
The fraction of the GNPs exocytosed was calculated as illustrated inFig. 2.Nanoparticle uptake variation for citrate-capped and peptide-capped nanoparticles.
Fig. 3. Exocytosis of peptide-capped GNPs. Dynamics of exocytosis process following one
and six hours. A. Number of GNPs exocytosed per cell after one hour and 6 h. B. Fraction
of GNPs exocytosed per cell after 6 h.
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for cells targeted with peptide-capped GNPs. Hence, the enhanced
retention of NPs within cells can be used for improved therapeutics in
radiation therapy and chemotherapy.
In conclusion, our results showed that the functionalization of
GNPs with RME peptides enhanced the NP uptake by ﬁve-fold. It was
also found that the fraction of NPs exocytosed was lower by a factor of
two for cells targeted with peptide-capped NPs in comparison to
citrate-capped (non-targeted) NPs. This prolonged intracellular reten-
tion due to peptide functionalization would allow NPs to exert their
desired applications more efﬁciently in cells, especially during drug
delivery. Hence, a proper understanding of the endocytosis and exocy-
tosis dynamics will shed more light on the design of GNPs in demand
for cancer therapeutic applications.
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